279 related articles for article (PubMed ID: 27502866)
21. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
22. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
23. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
[TBL] [Abstract][Full Text] [Related]
25. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.
Vranckx P; White HD; Huang Z; Mahaffey KW; Armstrong PW; Van de Werf F; Moliterno DJ; Wallentin L; Held C; Aylward PE; Cornel JH; Bode C; Huber K; Nicolau JC; Ruzyllo W; Harrington RA; Tricoci P
J Am Coll Cardiol; 2016 May; 67(18):2135-2144. PubMed ID: 27151345
[TBL] [Abstract][Full Text] [Related]
26. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
27. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
28. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
29. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
[TBL] [Abstract][Full Text] [Related]
30. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
[TBL] [Abstract][Full Text] [Related]
31. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.
Frampton JE
Drugs; 2015 May; 75(7):797-808. PubMed ID: 25895464
[TBL] [Abstract][Full Text] [Related]
32. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
Correa S; Bonaca MP; Scirica BM; Murphy SA; Goodrich EL; Morrow DA; O'Donoghue ML
J Thromb Thrombolysis; 2019 Apr; 47(3):353-360. PubMed ID: 30511258
[TBL] [Abstract][Full Text] [Related]
35. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
36. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial.
Clemmensen P; Roe MT; Hochman JS; Cyr DD; Neely ML; McGuire DK; Cornel JH; Huber K; Zamoryakhin D; White HD; Armstrong PW; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):695-705.e5. PubMed ID: 26386793
[TBL] [Abstract][Full Text] [Related]
38. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.
Ungar L; Clare RM; Rodriguez F; Kolls BJ; Armstrong PW; Aylward P; Held C; Moliterno DJ; Strony J; Van de Werf F; Wallentin L; White HD; Tricoci P; Harrington RA; Mahaffey KW; Melloni C
J Am Heart Assoc; 2018 Dec; 7(24):e009609. PubMed ID: 30526198
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial).
Hinohara TT; Roe MT; White HD; Fox KAA; Bhatt DL; Hamm C; Gurbel PA; Aylward PE; Wiviott SD; Huber K; Neely ML; Ohman EM
Am J Cardiol; 2018 Oct; 122(8):1322-1329. PubMed ID: 30135019
[TBL] [Abstract][Full Text] [Related]
40. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
